Immunocore
- Market cap
- 1.51B
- P/E (TTM)i
- -79.49
- P/Bi
- 3.61
- EPSi
- -0.71
- Div yieldi
- 0.00%
- 52W posi
- 14%
Anonymous reader poll. Unscientific, not investment advice.
About Immunocore
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. the firm's lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
- Founded
- 2021
- CEO
- Dr. Bahija Jallal, PhD
- Employees
- 524
- Headquarters
- Abingdon, Oxfordshire, United Kingdom of Great Britain and Northern Ireland (the)
- Fiscal year end
- 12-31
- Website
- immunocore.com
Company profile
- Exchange
- US
- Symbol
- IMCR
- Market-cap rank
- #2968
- Listing date
- 2021-02-05
- Market cap
- 1.51B
- Float cap
- 1.35B
- Shares out
- 51.50M
- Float shares
- 45.83M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.